CA-CEPTON-TECHNOLOGIES
11.11.2021 15:02:12 CET | Business Wire | Press release
Cepton Technologies, Inc. announced today that it has been named a CES® 2022 Innovation Awards Honoree in the Vehicle Intelligence & Transportation category for its Nova lidar , a miniature, wide field of view lidar sensor for near-range applications. The announcement was made ahead of CES 2022 , a global consumer electronics and consumer technology trade show that will be held from January 5-8 in Las Vegas, NV and digitally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005540/en/
The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)® , is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. An elite panel of industry expert judges , including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design. The Nova lidar has been selected among a record high number of submissions to this year’s program, signifying the weight of Nova’s technology and design value for the automotive market.
Nova features a miniature form factor and a wide field of view, making it ideally suited for seamless integration into modern vehicles. With a target volume price point under $100, Nova sets a worldwide benchmark with its unprecedented combination of compactness, field of view coverage and targeted affordability.
Nova is designed to help minimize perception blind spots to enhance advanced driver assistant systems (ADAS) and autonomous driving (AD) capabilities.
It aims to address major gaps in proximity detection of objects with current sensor technologies such as cameras, radars and ultrasonic sensors. Powered by Cepton’s patented Micro Motion Technology (MMT® ) , Nova enables high-resolution 3D imaging to accurately detect small children, on-road objects, protrusions and road edges etc. to help increase vehicle safety and enable a higher level of autonomy. Compared to some other near-range lidars , Nova achieves a higher field of view in both horizontal (120°) and vertical (60°) directions with significantly lower size, power and weight.
Benefiting from the maturity of MMT and Cepton’s proprietary lidar engine ASIC for advanced signal processing, Nova is built to meet the stringent requirements of the automotive industry. An automotive-grade lidar , it supports ASIL-B functional safety and consumes <3.5 W (typical power). Nova can be elegantly embedded all around an automobile to provide a complete 360° view of a vehicle’s immediate surroundings, without disrupting the vehicle’s design aesthetics.
In addition to automotive applications, Nova can also enable autonomous robotics and ground vehicles for industrial applications.
Earlier this year, Nova was a second-place award winner at the 2021 Tech.AD Europe Awards , in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies.
“The key value proposition of the Nova lidar is its combination of a wide horizontal and vertical field of view, the very compact size, the low power consumption and an attractive volume price,” said Dr. Jun Pei, CEO of Cepton.
“With that, we hope to significantly enhance vehicle safety in everyday passenger cars by making Nova a mass-market lidar solution . In addition, it uses a scaled version of Cepton’s patented MMT architecture that is already in use in the long-range lidars that we are supplying in our major ADAS lidar program with our key OEM customer . We believe that this means that the core technology enabling Nova has reached a high maturity level and is licensable to manufacturing partners, especially automotive Tier 1s .”
Detailed information about the CES 2022 Innovation Awards honorees can be found at CES.tech/innovation . In January 2022, Cepton will join many other honorees in showcasing their products in the Innovation Awards Showcase area at CES 2022. At the Cepton Booth (#5518, LVCC – West Hall), Cepton will also showcase Nova alongside its comprehensive portfolio of lidar solutions for smart mobility , covering automotive and smart infrastructure applications . Please visit the Cepton website for more information.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom